SAIT101
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for SAIT101, covering 2020-02-17 to 2020-10-08. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 3]